64 results about "Combination Medication" patented technology

This invention relates to the application of mitochondrial extracts in reversing drug resistance in solid tumors. By combining mitochondrial extracts with chemotherapeutic drugs, the resistance of chemotherapeutic-resistant solid tumors to these drugs can be reversed. Compared to using mitochondrial extracts and chemotherapeutic drugs alone, this method effectively enhances drug efficacy, thereby overcoming chemotherapeutic resistance in solid tumors. This invention, through intervention with mitochondrial extracts in different chemotherapeutic-resistant solid tumor cell lines, has verified that the combined use of mitochondrial transplantation and chemotherapeutic drugs can reverse chemotherapeutic resistance, thereby improving the efficacy of chemotherapy and opening up the possibility of continued treatment for patients with advanced solid tumors who are resistant to chemotherapeutic drugs.

The application provides a combination drug of a PLA2G7 inhibitor and a chemotherapeutic drug and its use in resisting triple-negative breast cancer, and belongs to the technical field of medicines. The combination drug is a PLA2G7 inhibitor and a chemotherapeutic drug in the same or different specifications of unit preparations for simultaneous or separate administration, and a pharmaceutically acceptable carrier. The application first discovers and proves that the PLA2G7 inhibitor Darapladib can significantly enhance the anti-tumor activity of paclitaxel, 5-fluorouracil or cisplatin on triple-negative breast cancer, and meanwhile, the combination of the PLA2G7 inhibitor and paclitaxel has a synergistic effect in down-regulating the phosphorylation level of STAT3 protein in cancer cells and inhibiting the growth and proliferation of cancer cells; the combination of the PLA2G7 inhibitor and 5-fluorouracil also shows a synergistic effect in inhibiting the growth and proliferation of cancer cells. The application provides a new and effective combination drug strategy for improving the treatment effect of the chemotherapeutic drug on triple-negative breast cancer.

The application provides a combined drug, a liposome, a biomimetic liposome, a preparation method of the combined drug, the liposome and the biomimetic liposome, and application of the combined drug, the liposome and the biomimetic liposome in preparation of an anti-breast cancer lung metastasis drug, and belongs to the technical field of biological medicines. The combined drug comprises panatinib and ginsenoside Rg3. The application further provides a liposome PNT-Rg3-Lipo for simultaneously loading the two, and a biomimetic liposome MM / PNT-Rg3-Lipo coated with a macrophage membrane. Experiments show that the combination of the two can synergistically regulate chemokines CXCL1 , CXCL2 and CXCL11 , and the effect is better than the sum of the single use. The MM / PNT-Rg3-Lipo has uniform particle size, retains integrin alpha 4 / beta 1 functional proteins, can target lung metastases, significantly reduces metastatic nodules, and has good biocompatibility. The application provides an effective new strategy for resisting breast cancer lung metastasis.

This invention discloses a trimethyl chitosan-hyaluronic acid-FMNL2 siRNA nanomedicine and its applications. The siRNA molecule consists of a sense strand and an antisense strand, which are anti-complementary to form a double-stranded RNA structure. Each of the sense and antisense strands independently contains two pendant deoxythymidines at its 3' end. The nanomedicine uses trimethyl chitosan as its core framework, efficiently encapsulating the siRNA molecule through electrostatic interactions, and then modifying hyaluronic acid through electrostatic interactions to form core-shell structured nanoparticles. This invention forms a complete technology chain from target validation, siRNA sequence design, nanodelivery system construction, in vivo and in vitro efficacy verification to the development of combination drug strategies. It also provides quantifiable efficacy evaluation biomarkers, offering a clear basis for clinical patient screening and efficacy monitoring.

The present disclosure relates to methods of treating cancers comprising coadministration of mirdametinib or a pharmaceutically acceptable salt form thereof, and lifirafenib or a pharmaceutically acceptable salt form thereof, to a patient in need thereof. Also disclosed are pharmaceutical compositions of mirdametinib or a pharmaceutically acceptable salt form thereof, and lifirafenib or a pharmaceutically acceptable salt form thereof, for use in such cancer treatment, as well as uses of these compounds for manufacture of medicaments for the treatment of cancers.

The application discloses a composition containing a peripheral vasodilator and a 5alpha-reductase inhibitor, effectively solves the transdermal inhibition of the peripheral vasodilator on the 5alpha-reductase inhibitor by adding a specific penetration enhancer, improves the transdermal rate of the active ingredients in the pharmaceutical composition by proportion adjustment, greatly improves the synergistic effect of local combined medication, avoids the side effects brought by oral 5alpha-reductase inhibitor, and improves the safety of the medicine.

The present application relates to the technical field of artificial intelligence, and particularly relates to an individualized medication prediction method based on artificial intelligence, comprising: acquiring a plurality of standard historical medical data sets; acquiring metabolic capacity scores and drug metabolism rates corresponding to all data groups; training to obtain relationship models corresponding to all standard historical medical data sets; acquiring liver metabolism parameters, gene expression parameters and each drug name in a treatment scheme of a patient to obtain a drug metabolism rate; and determining a corresponding prediction drug amount determination method according to whether the drug types in the treatment scheme have a competitive relationship. The present application integrates drug metabolism enzyme-related gene expression and liver metabolism function, simultaneously incorporates drug absorption competition and metabolism enzyme competition when drugs are used in combination, corrects the final output prediction drug amount when drugs are used in combination, so that the model is more suitable for the actual drug use scene, and the accuracy of the prediction result is increased.

This invention provides a drug interaction prediction method based on a bidirectional cross-view attention network, belonging to the field of drug interaction prediction technology. The method first constructs a Morgan fingerprint similarity view of the drug, an original DDI view, and a multi-scale diffusion view based on personalized PageRank. Then, a graph convolutional network with shared weights is used to co-encode the multiple views, generating a unified drug embedding representation. Finally, a bidirectional cross-view attention mechanism is used to achieve fine-grained interaction and alignment between the structural and attribute views, and interaction prediction is completed via a multilayer perceptron. This invention effectively alleviates the sparsity problem of the DDI network through multi-scale topology enhancement and achieves complementary enhancement between views using bidirectional cross-view attention, significantly improving the accuracy and generalization ability of drug interaction prediction. It can provide reliable technical support for drug development screening and clinical combined drug safety assessment.

The application belongs to the technical field of biological medicine, and provides application of combined use of tocopherol and mulberroside C in preparation of a drug for treating liver cancer, which is combined use of tocopherol and mulberroside C in preparation of a drug for treating liver cancer. Through in-vitro cell experiments, the growth inhibition effect of tocopherol and mulberroside C on liver cancer cells is evaluated; the results show that tocopherol and mulberroside C can inhibit the growth activity of liver cancer cells to achieve the purpose of treating liver cancer.

The purpose of the present disclosure is to develop a new combination therapy that exerts a superior antitumor effect as compared to administration of an anti-CD26 antibody alone. In order to assess both the function of an immune checkpoint inhibitor and the antitumor effect of an anti-CD26 antibody, it is necessary to be provided with both a binding site on a human CD26 molecule and an immune system of the same lineage of a cancer cell. Thus, in order to acquire data of an immune checkpoint inhibitor and an anti-CD26 antibody, it is essential to perform analysis in a human immune system and a human tumor cell line. The present inventors have made an attempt to produce a human immune system mouse to be used as a model animal for confirming the effect of the combination between ICI and an anti-CD26 antibody, and have successfully produced a model mouse superior for generating human T-cells. Next, the present inventors have studied the effect of combining an immune checkpoint inhibitor and an anti-CD26 antibody in a tumor bearing model by using said mouse. As a result, it was found that an agent using said combination has a synergistic effect that is stronger than when the respective agents are used individually.

This invention belongs to the field of biomedical technology, specifically relating to triptolide liposomes (TP-lipo), their combined use, and their application in the prevention and treatment of tumors. To enhance the efficacy of triptolide in the treatment and prevention of tumors such as pancreatic cancer, cervical cancer, ovarian cancer, and colorectal cancer, and to improve its bioavailability and clinical application while reducing toxicity, this invention uses HSPC, DOPS, and cholesterol as liposome components to encapsulate triptolide monomers, thus preparing TP-lipo. Experiments have shown that TP-lipo exhibits anti-tumor activity: it directly kills tumor cells and reverses the immunosuppressive microenvironment, making it a potential drug for tumor treatment. TP-lipo, when used in combination with PD-1 antibodies, or in combination with radiotherapy, chemotherapy, or surgery, demonstrates a potent and synergistic anti-tumor effect with low toxicity. Therefore, the TP-lipo of this invention provides more clinical strategies for tumor treatment.

The present application relates to a kind of combined drug composition for improving or treating follicular lymphoma and its application, the active component of the combined drug composition is composed of first active component and second active component;The first active component is selected from any one or combination of at least two of ritanserin or its pharmaceutically acceptable salt, isomer, solvate, metabolite;The second active component is selected from any one or combination of at least two of donepezil or its pharmaceutically acceptable salt, isomer, solvate, metabolite.The combined drug composition has excellent improvement or treatment effect of follicular lymphoma, two active components not only can reduce the dosing of ritanserin or donepezil when inhibiting follicular lymphoma, improve drug safety, but also have more significant inhibiting effect of follicular lymphoma than using single active component, reach the effect of synergistic promotion.

This invention discloses a synergistic antitumor drug composition and its application. The composition consists of cisplatin and atorvastatin, with a molar ratio of cisplatin to atorvastatin of 1:1.5. This invention provides a combination of drug concentrations at low concentrations to treat cancer cells, inhibit cancer cell proliferation, activate and induce apoptosis. Compared with traditional methods, this method reduces cellular drug resistance, has a lower concentration, is safer and more effective, and reduces the toxic reactions caused by high concentrations of drugs.

The present application relates to the use and combination of Shenghua Xinggao and mifepristone in treating embryo residue after medical abortion. The use of Shenghua Xinggao and mifepristone in treating embryo residue after medical abortion can make the blood flow signal of residue disappear and HCG decrease rapidly, thereby greatly reducing the risk of surgical curettage for patients, and has important clinical value.

The application belongs to the technical field of biological medicine, and particularly relates to a binding molecule targeting CCL5 and application of the binding molecule in combination with drugs in treatment of Th2-type inflammation related diseases. The application discloses use of a binding molecule targeting CCL5 or a pharmaceutical composition comprising the binding molecule in preparation of a product having one or more of the following functions: 1) prevention and / or treatment of Th2-type inflammation related diseases; 2) reduction of skin lesion tissue thickness; 3) reduction of clinical score of atopic dermatitis; 4) reduction of scratching behavior; 5) reduction of tissue damage; 6) alleviation of inflammatory reaction and inhibition of expression of inflammatory factors; and 7) reduction of inflammatory cell infiltration. The binding molecule targeting CCL5 or the pharmaceutical composition comprising the binding molecule has important value in prevention and treatment of immune inflammatory diseases such as atopic dermatitis, allergic rhinitis, asthma, food allergy or drug allergy.

This invention relates to the field of biomedical technology, specifically to an antifungal nanoparticle, a combination drug, and its application. The antifungal nanoparticle is prepared by covalently linking the aptamer AU1 to drug-loaded silk fibroin nanoparticles via amide bonds. The mass ratio of the drug-loaded silk fibroin nanoparticles to the aptamer AU1 is 20:0.5~2.0. The antifungal nanoparticles of this invention are prepared by a desolvation method using voriconazole-loaded silk fibroin nanoparticles, and the targeting aptamer AU1 is attached to their surface using a carbodiimide chemical cross-linking method. This allows for specific recognition of Candida albicans, increasing drug accumulation at the infection site. Further combination with methylene blue-mediated photodynamic therapy can disrupt biofilm structures, enhance nanoparticle penetration, achieve synergistic bactericidal activity, and reduce systemic toxicity, providing a novel, highly effective, and low-toxicity treatment strategy for fungal biofilm infections.

The application provides a method for synchronously detecting multiple cell death modes in a tissue slice based on multiplex immunofluorescence, and belongs to the technical field of biological detection. The application realizes the synchronous labeling and visualization of multiple cell death modes in a single tissue slice, significantly improves the detection efficiency and saves precious samples; by integrating key biomarkers covering main cell death modes in the same detection system, a self-defined interpretation scheme based on multi-marker expression combination is constructed, effectively reducing the error caused by non-specific expression of a single marker, improving the reliability and rationality of the death mode classification, and providing a general solution for rapid screening of complex cell death networks. The application is suitable for anticancer drug efficacy evaluation, combination drug regimen screening and disease mechanism research, and has important scientific research value and clinical conversion prospect.

The application discloses a kind of sea cucumber peptide with antitumor activity and ginsenoside composition preparation method and its application, it is related to biological activity material complex technical field, composition includes directional enzymatic sea cucumber oligopeptide, biotransformation rare ginsenoside and tumor microenvironment response carrier;Sea cucumber oligopeptide is proportioned with Rg3, Rh2, Compound K, Rk1, Rg5 and the like saponin, and is loaded by hyaluronic acid / folic acid modified disulfide bond crosslinking chitosan-lipid carrier, is accelerated release under weak acid, high glutathione or hyaluronidase condition.This composition has good stability and delivery efficiency, and can be used for antitumor auxiliary preparation, functional food and combined drug research.

The application discloses an FBXO48 inhibitor which can effectively enhance the curative effect of paclitaxel under lung cancer hypoxia, and particularly relates to a combined use of an FBXO48 inhibitor (BC1618) and a chemotherapeutic drug (paclitaxel) and application of the combined use in preparation of a drug for treating hypoxia-driven drug-resistant tumors. The application discloses for the first time that FBXO48 up-regulates CA9 and glycolysis pathway through a CAMKK2-pAMPK alpha-HIF1 alpha signal axis, and mediates drug resistance of tumor cells to chemotherapeutic drugs such as paclitaxel under hypoxia. The FBXO48 inhibitor (BC1618) can restore the sensitivity of tumor cells to chemotherapeutic drugs by blocking the signal axis, and shows a significant synergistic effect in patient-derived tumor organoids and mouse xenograft models. The application provides a brand-new combined treatment strategy for overcoming the chemotherapeutic resistance caused by the tumor hypoxic microenvironment.

The application discloses a drug interaction prediction and dose reference information generation method, system and device, and the method comprises the following steps: acquiring parameters of a Bruton's tyrosine kinase inhibitor as a target drug and an antiretroviral drug as an interaction drug; constructing and verifying a basic physiological pharmacokinetic model of each drug; integrating inhibition or induction parameters of the interaction drug on corresponding enzymes, constructing and verifying an interaction prediction model; running the verified model to simulate and calculate predicted exposure data of the target drug when the drugs are used in combination; and generating dose reference information meeting preset bioequivalence conditions by iteratively adjusting dose parameters of the target drug and re-simulating. The application realizes automatic, quantitative prediction and personalized dose scheme generation of specific drug combination interactions, and can provide key decision support for clinical combination drug use.

This invention relates to the field of pharmaceutical biotechnology, providing the application of aminoquinoline compounds (such as hydroxychloroquine and chloroquine) in the preparation of drugs for treating hyperparathyroidism. These compounds restore the expression of calcium-sensitive receptors (CaSRs) on the cell membrane surface by inhibiting the lysosomal degradation pathway of CaSRs in parathyroid cells. Experiments have confirmed that 4-aminoquinoline compounds, used alone or in combination with calcimimetics (such as cinacalcet), significantly reduce serum PTH and calcium levels in a model of refractory secondary hyperparathyroidism (SHPT) and inhibit glandular hyperplasia. In particular, the combination therapy regimen exhibits a significant synergistic effect, effectively reversing calcimimetics resistance. This invention is the first to discover a novel use for the antimalarial / antirheumatic drug hydroxychloroquine in the treatment of hyperparathyroidism, realizing a new use for an existing drug; and providing a safe and effective new drug treatment strategy for clinically refractory SHPT.

The application discloses application of a pathogenic transposable element pL1HS as a lung squamous carcinoma biomarker and a therapeutic target. The 5'-UTR region of the pathogenic transposable element pL1HS has a nucleic acid sequence as shown in SEQ ID NO. 1, and specific detection primers are shown in SEQ ID NO. 2 and SEQ ID NO. 3 respectively. Animal experiments prove that the combined application of the reverse transcription transposition inhibitor nevirapine and the cGAS inhibitor can significantly inhibit the growth of lung squamous carcinoma. The pathogenic transposable element pL1HS can be used as a novel molecular marker in the diagnostic application dimension, and provides a precise detection index for early screening, pathological typing and prognosis judgment of lung squamous carcinoma. In the treatment application dimension, the target intervention strategy for pL1HS, especially the combined medication scheme of multi-pathway inhibitors, opens up a new direction.

The present application relates to a kind of combination drug composition for preventing or treating diffuse large B-cell lymphoma and its application, the active component of the combination drug composition is composed of first active component and second active component;The first active component is selected from selinexor or any one or at least two combinations of its pharmaceutically acceptable salt, isomer, solvate, metabolite;The second active component is selected from ritonavir or any one or at least two combinations of its pharmaceutically acceptable salt, isomer, solvate, metabolite.The combination drug composition has excellent treatment effect of diffuse large B-cell lymphoma, not only can reduce the dosage of selinexor, improve the safety of drug, but also has more significant inhibitory effect on diffuse large B-cell lymphoma than using single selinexor.

The present invention belongs to the field of medicine and relates to use of an iron-loaded carbon nanoparticle suspension injection for combined administration. The iron-loaded carbon nanoparticle suspension injection is administered in combination with an anticancer drug to inhibit tumor growth. In the combined administration, the anticancer drug is administered orally or intravenously, and the iron-loaded carbon nanoparticle suspension injection is administered via intratumoral injection. After the iron-loaded carbon nanoparticle suspension injection is injected into a tumor, it is found that the anticancer drug administered orally or intravenously is enriched in the tumor, thereby increasing the concentration of the anticancer drug in the tumor, enabling the anticancer drug to more accurately act on the tumor site, and reducing the dose of the anticancer drug and its toxic side effects on normal cells and tissues. The combined administration of the iron-loaded carbon nanoparticle suspension injection and the anticancer drug has a synergistic effect.

The present invention relates to a compound capable of preventing or treating lung cancer by inhibiting the expression or activity of Anoctamin 1 (ANO1), which is a calcium-activated chloride channel, and epidermal growth factor receptor (EGFR), which is an epithelial growth factor receptor. The compound of the present invention can be advantageously used alone as a composition for preventing or treating lung cancer, can be used per se as a dual-target anticancer drug for ANO1 and EGFR, and can also be used as an adjuvant or a combination preparation in combination with an EGFR-targeted therapeutic agent.

This invention relates to a screening method and application of traditional Chinese medicine inhibitors against carbapenem-resistant Klebsiella pneumoniae, belonging to the field of biomedical technology. Based on a high-throughput screening system for carbapenem-resistant Klebsiella pneumoniae inhibitors constructed using a fluorescent probe for carbapenemase activity detection, the invention successfully screened out mulberry bark as a carbapenemase inhibitor, sanghorn ketone G. When used in combination with meropenem, this inhibitor significantly inhibits the metabolism of meropenem by carbapenem-resistant Klebsiella pneumoniae, greatly enhancing the inhibitory efficiency of meropenem against the strain, providing a highly effective and valuable combination therapy for clinical treatment of carbapenem-resistant Klebsiella pneumoniae infection.

The application provides a drug-loaded gelatin nanogel, a biomimetic nanogel and a preparation method and combined drug and use thereof, and belongs to the technical field of biological medicines.The application forms a drug-loaded gelatin nanogel by reacting all-trans retinoic acid with pirfenidone and gelatin, cooperatively inhibits the activation of pancreatic stellate cells and blocks the pro-fibrosis signal pathway, realizes the reversal of the fibrosis microenvironment of pancreatic cancer, coats the drug-loaded gelatin nanogel on the membrane of activated pancreatic stellate cells to construct a biomimetic nanogel, so that the biomimetic nanogel has active targeting, and the drug delivery efficiency and the treatment effect are significantly improved, and the drug-loaded gelatin nanogel, the biomimetic nanogel and a chemotherapeutic drug are combined to treat pancreatic cancer, have a significant anti-tumor effect, and the combined treatment of the biomimetic nanogel and gemcitabine has a synergistic anti-tumor effect.The gelatin realizes effective regulation of the dense fibrosis microenvironment of pancreatic cancer, and provides a new feasible strategy for the treatment of pancreatic cancer.

This invention discloses the application of LukS-PV and its combination with a PD-1 inhibitor in the preparation of drugs for treating hepatocellular carcinoma, belonging to the field of biomedical technology. LukS-PV of this invention exerts its anti-tumor effect by promoting the polarization transformation of tumor-associated macrophages from M2 to M1 types, thereby improving the tumor immunosuppressive microenvironment. Furthermore, the combined use of LukS-PV and a PD-1 inhibitor can enhance CD8+ T cell infiltration and anti-tumor immune function, alleviate T cell exhaustion, and improve the therapeutic effect of liver cancer.

This invention belongs to the field of liver disease research and biomedicine, specifically relating to the application of reagents targeting and inhibiting OXCT1 in combination with BHB or pharmaceutically acceptable salts thereof in the preparation of anti-HCC drugs. The reagents inhibiting OXCT1 include: siRNA, shRNA, antisense nucleic acid, and gene editing reagents that reduce OXCT1 expression; and small molecule inhibitors, peptides, antibodies, or fusion proteins that inhibit OXCT1 enzyme activity. This invention proposes a novel therapeutic strategy of targeting and inhibiting OXCT1 in combination with BHB. Studies have shown that targeting and inhibiting OXCT1 can block the pro-cancer metabolic pathway of BHB, reducing the effective concentration of BHB for its anti-cancer effect, enabling it to achieve significant anti-cancer effects at clinically tolerable concentrations and exert a synergistic anti-tumor effect. This invention solves the problem of limited clinical application of high-concentration BHB and provides a new combination therapy regimen with clinical translational potential for hepatocellular carcinoma.

The present application provides a set of complete innovative technical solutions from target discovery to treatment intervention for the immune escape and drug resistance recurrence problems existing in the clinical treatment of multiple myeloma (MM). It is found that Siglec7 is mainly highly expressed on the surface of NK cells, and the proportion and expression intensity of Siglec7 positive NK cells are significantly higher than those of complete remission and non-tumor controls; further, Siglec7 monoclonal antibody is prepared, and when the anti-Siglec7+CD38 monoclonal antibody (such as daratumumab) is used, a significant synergistic anti-tumor effect can be produced in vitro and in vivo. The technical solution completely constructs the research and development chain of "marker discovery-target verification-drug development-treatment application", and provides a new target, specific antibody drug and innovative combined drug regimen for the precise diagnosis, prognosis and especially immunotherapy of refractory and relapsed patients with multiple myeloma, which has great clinical transformation value and market prospect.